Found 1873 clinical trials
Study to Evaluate the Safety Tolerability Pharmacokinetics and Pharmacodynamics of CC-94676 in Subjects With Metastatic Castration-Resistant Prostate Cancer
This is a first in human study to assess the safety, tolerability, PK, PD and preliminary efficacy of CC-94676 in men with progressive metastatic castration-resistant prostate cancer.
- 0 views
- 19 Feb, 2024
- 6 locations
MRI-guided Focal Laser Ablation
Magnetic resonance imaging-guided focal laser ablation of prostate cancer.
- 0 views
- 19 Feb, 2024
- 1 location
18F-PSMA-1007 PET Imaging to Detect Primary Prostate Cancer
To study the added value of 18F-PSMA-1007 PET to mpMRI in the detection of local prostate cancer lesions.
- 0 views
- 19 Feb, 2024
- 1 location
PRO-MERIT (Prostate Cancer Messenger RNA Immunotherapy)
Open-label, multicenter, dose titration and expansion three-arm trial to evaluate the safety, tolerability, immunogenicity, and preliminary efficacy of W_pro1 cancer vaccine (W_pro1) in patients with metastatic castration resistant prostate cancer (mCRPC) W_pro1 in combination with goserelin acetate with or without cemiplimab, in patients with high-risk, localized prostate cancer (LPC)
- 2 views
- 19 Feb, 2024
- 16 locations
Study of PSMA PET/MR Guided Stereotactic Body Radiation Therapy With Simultaneous Integrated Boost (SBRT-SIB) for High-Intermediate and High Risk Prostate Cancer
This is a single-arm Phase II clinical trial assessing the clinical efficacy of prostate specific membrane antigen (PSMA) PET/MR guided MR-LINAC based SBRT-SIB with planned accrual of 50 patients.
- 16 views
- 19 Feb, 2024
- 1 location
Oral EPI-7386 in Patients With Metastatic Castration-Resistant Prostate Cancer
This is a phase I, clinical research study of EPI-7386, an investigational drug being studied as a treatment for patients with prostate cancer. All patients in the study will receive EPI-7386. Since this is the first study of EPI-7386 in humans, there is no information about how it affects people …
- 0 views
- 19 Feb, 2024
- 5 locations
Lutetium-177-PSMA-I&T in Oligo-metastatic Hormone Sensitive Prostate Cancer
Radioligand therapy (RLT) using Lutetium-177 labelled PSMA is a promising new therapeutic approach to treat metastatic prostate cancer. This tumor-specific treatment is directed against prostate-specific membrane antigen (PSMA), which is overexpressed in prostate cancer cells.
- 4 views
- 19 Feb, 2024
- 4 locations
18F-DCFPyL PET/CT Impact on Treatment Strategies for Patients With Prostate Cancer
The main purpose of this phase II trial study is to determine whether a positron emission tomography (PET)/computed tomography (CT) scan using 18F-DCFPyL affects the clinical management plan in Veterans. In this study, the management plan prior to and after 18F-DCFPyL PET/CT will be recorded by specific questionnaires and corresponding …
- 0 views
- 19 Feb, 2024
- 1 location
EBRT and HDR Brachytherapy for Unfavorable-intermediate High and Very High-risk Prostate Cancer
This study is trying to find out if the combination of Androgen deprivation therapy (ADT), MRI guided high dose radiation (HDR) brachytherapy treatment (internal radiation implant procedure) and external beam radiation therapy (EBRT) treatments lead to less side effects. This study is also looking at patient outcomes, quality of life, …
- 0 views
- 19 Feb, 2024
- 1 location
Pilot Study of an Implantable Microdevice for Evaluating Drug Responses in Situ in Prostate Cancer
In this research study, is assessing the feasibility of using an MR-guided implantable microdevice to measure tumor response to chemotherapy and other clinically relevant drugs in participants that have prostate cancer and are scheduled for a radical prostatectomy. The name of the study intervention involved in this study is: Implantation …
- 2 views
- 19 Feb, 2024
- 1 location